Hostname: page-component-586b7cd67f-t8hqh Total loading time: 0 Render date: 2024-11-28T08:37:54.510Z Has data issue: false hasContentIssue false
  • English
  • Français

Predictors of Mortality From Community-Onset Bloodstream Infections Due to Extended-Spectrum β-Lactamase-Producing Escherichia coli and Klebsiella pneumoniae

Published online by Cambridge University Press:  02 January 2015

Anucha Apisarnthanarak ,
Pattarachai Kiratisin  and
Linda M. Mundy
Anucha Apisarnthanarak*
Affiliation:
Division of Infectious Diseases, Faculty of Medicine, Thammasat University Hospital, Pratumthani, Thailand
Pattarachai Kiratisin
Affiliation:
Department of Microbiology, Faculty of Medicine, Siriraj Hospital, Mahidol University, Bangkok, Thailand
Linda M. Mundy
Affiliation:
St. Louis University School of Public Health, St. Louis, Missouri
*
Division of Infectious Diseases, Faculty of Medicine, Thammasat University Hospital, Pratumthani, Thailand, 12120 ([email protected])
Get access Rights & Permissions [Opens in a new window]

Abstract

In a cohort study of 36 patients with community-onset extended-spectrum β-lactamase (ESBL)–producing Escherichia coli or Klebsiella pneumoniae bloodstream infections, we found that predictors of mortality were community-onset infection with ESBL-producing K. pneumoniae pathogens (P = .02) and failure to receive an initial empirical regimen that included either β-lactam and β-lactamase–inhibitors or a carbapenem (P = .04).

Type
Concise Communications
Information
Infection Control & Hospital Epidemiology , Volume 29 , Issue 7 , July 2008 , pp. 671 - 674
Copyright
Copyright © The Society for Healthcare Epidemiology of America 2008

Access options

Get access to the full version of this content by using one of the access options below. (Log in options will check for institutional or personal access. Content may require purchase if you do not have access.)

References

1.Apisarnthanarak, A, Kiratisin, P, Saifon, P, Kitphati, R, Dejsirilert, S, Mundy, LM. Clinical and molecular epidemiology of community-onset extended spectrum β-lactamase producing Escherichia coli in Thailand: a case-case-control study. Am J Infect Control 2007;35:606–612.Google Scholar
2.Colodner, R, Rock, W, Chazan, B, et al. Risk factors for the development of extended-spectrum β-lactamase-producing bacteria in nonhospitalized patients. Eur J Clin Microbiol Infect Dis 2004;23:163–167.Google Scholar
3.Calbo, E, Romany, V, Xercavins, M, et al. Risk factors for community-onset urinary tract infections due to Escherichia coli harboring extended-spectrum β-lactamases. J Antimicrob Chemother 2006;57:780–783.CrossRefGoogle ScholarPubMed
4.Rodriguez-Bano, J, Navarro, MD, Romero, L, et al. Bacteremia due to extended-spectrum beta-lactamase-producing Escherichia coli in the CTX-M era: a new clinical challenge. Clin Infect Dis 2006;43:1407–1414.CrossRefGoogle Scholar
5.Apisarnthanarak, A, Kiratisin, P, Saifon, P, Kitphati, R, Dejsirilert, S, Mundy, LM. Predictors of mortality among patients with community-onset infection due to extended-spectrum β-lactamase-producing Escherichia coli in Thailand. Infect Control Hosp Epidemiol 2008;29:80–82.CrossRefGoogle ScholarPubMed
6.Garner, JS, Jarvis, WR, Emori, TG, et al. Centers for Disease Control definitions for nosocomial infections, 1988. Am J Infect Control 1988;16:128–140.CrossRefGoogle ScholarPubMed
7.Kollef, MH. Inadequate antimicrobial treatment: an important determinant of outcome for hospitalized patients. Clin Infect Dis 2000;31(suppl4):S131–138.Google Scholar
8.Clinical and Laboratory Standards Institute (CLSI). Performance Standards for Antimicrobial Susceptibility Testing:17th informational supplement. Wayne, PA: CLSI; 2007:M100–S17.Google Scholar